---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-166322"
form_type: "8-K"
ticker: null
cik: "0001293971"
company_name: "bluebird bio, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:24:11.280112+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# bluebird bio appoints Michael Cloonan to Board as Class I director effective June 20, 2024

## Summary
- Michael Cloonan appointed as Class I director, effective June 20, 2024.
- Annual retainer of $45,000; initial grant of 74,775 stock options and 37,350 RSUs.
- Stock options and RSUs vest ratably over three years; standard indemnification agreement.
- No family relationships with other directors/officers, no reportable transactions.

## SEC filing metadata
- accession: 0001193125-24-166322
- form_type: 8-K
- cik: 0001293971
- company_name: bluebird bio, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293971/000119312524166322/0001193125-24-166322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293971/000119312524166322/d826411d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-166322
- JSON: https://secwatch.observer/filing/0001193125-24-166322.json
- Plain text: https://secwatch.observer/filing/0001193125-24-166322.txt

## Key facts
- Executive change
  Michael Cloonan was appointed as Class I director at bluebird bio, Inc..
  - Action: appointed
  - Role: Class I director
  source text: On June 20, 2024, the board of directors (the “Board”) of bluebird bio, Inc. (the “Company”) appointed Michael Cloonan to the Board as a Class I director, effective June 20, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000119312524166322/0001193125-24-166322-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.